Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of dupilumab in adults with chronic pruritus of unknown origin CPUO, a condition causing severe itching without a clear cause. This Phase 3 study includes two parallel, double-blind clinical trials involving men and women aged 18 to 90 years who have experienced severe itching for at least six months. The trials aim to compare dupilumab with a placebo while both groups also use a non-sedative antihistamine and moisturizer. After up to a 4-week screening, participants with severe itch enter a 4-week run-in period receiving antihistamines and moisturizers. Those still experiencing severe itching are randomly assigned to receive either dupilumab or placebo injections subcutaneously every two weeks for 24 weeks, alongside their existing treatments. Following this, all participants enter a 12-week follow-up period to monitor outcomes. Participants attend regular visits for assessments including itch severity ratings, quality of life questionnaires, and anxiety and depression scales. Researchers will measure changes in itch intensity, sleep disturbance, and life quality over time. Safety is closely monitored throughout the treatment and follow-up periods, with the total participation lasting up to 44 weeks.